SCIO Scios Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc.

SCIO 0.01000

0.0%

Aug 19 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: ubrx who wrote (949)	12/28/1998 11:50:00 PM
From: Miljenko Zuanic	Read Replies (1) of 1477

Jim: <<...the complete reasons for the suspension of the Fiblast N.A. stroke trials have never been fully explained. >> This is exactly what's worry me. :( Europe stroke trials is with different protocol (longer infusion, but I do not know rate or dose to compare it with NA trial), which may result in better positive effects and swing drug risk/benefit ratio and therapeutic index to acceptable level. Will see. <<I agree that the indications of PVD (peripherial vascular disease) and CAD (coronary artery disease) still hold much potential for Fiblast and VEGF121. Hopefully clinical trials will begin with the next few months. >> Correct me if I am wrong, but Scios&AHP started FIBLAST PVD/CAD PII trials in January 97. It is about time for results of this trial. Data from this trial are very important, imo. Even more if one consider their main competitor (CHIR), which recently (Nov. 9, 1998)started their rFGF-2 CAD PII trial. Recently, there was a loot of public noise about gene-therapeutic angiogenesis. GenVac (which license VEGF121 from SCIO) in collaboration with Parke-Davis (WL) completed safety PI (report from AHA) trial with AdVVEGF121.10 in CAD/bypass graft surgery. They are planing PII trials in CAD. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next